Literature DB >> 24400220

Rescue Living-donor Liver Transplantation for Liver Failure Following Hepatectomy for Hepatocellular Carcinoma.

See Ching Chan1, William Wei Sharr2, Albert Chi Yan Chan2, Kenneth Siu Ho Chok2, Chung Mau Lo1.   

Abstract

Liver failure following major hepatectomy for hepatocellular carcinoma is a known but uncommon mode of early treatment failure. When post-hepatectomy liver failure becomes progressive, the only effective treatment for rescuing the patient is liver transplantation. Deceased-donor liver transplantation in this situation is often not feasible because of the shortage of deceased-donor liver grafts. Proceeding with living-donor liver transplantation is an ethical challenge because of the possibility of donor coercion. In addition, tumor status, as confirmed by histopathological examination of the resected specimen, may indicate aggressive cancer that warns against rescue transplantation because of the increased chance of tumor recurrence. Here we describe four cases of rescue living-donor liver transplantation for liver failure after hepatectomy for hepatocellular carcinoma. The patients all survived the transplantation and were free from tumor recurrence after follow-up periods ranging from 6 months to 9 years. Our experience has shown that rescue living-donor liver transplantation for post-hepatectomy liver failure is feasible. Tumor status should be considered carefully because large tumors and tumors with macrovascular invasion are strong contraindications to rescue living-donor liver transplantation.

Entities:  

Keywords:  Hepatocellular carcinoma; Liver failure; Living-donor liver transplantation; Rescue

Year:  2013        PMID: 24400220      PMCID: PMC3881315          DOI: 10.1159/000343848

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  33 in total

1.  Transplantation of liver grafts from living donors into adults--too much, too soon.

Authors:  D C Cronin; J M Millis; M Siegler
Journal:  N Engl J Med       Date:  2001-05-24       Impact factor: 91.245

2.  High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation.

Authors:  Margarita Sala; Josep Fuster; Josep M Llovet; Miquel Navasa; Manel Solé; María Varela; Fernando Pons; Antoni Rimola; Juan Carlos García-Valdecasas; Concepció Brú; Jordi Bruix
Journal:  Liver Transpl       Date:  2004-10       Impact factor: 5.799

Review 3.  Liver resection and transplantation in hepatocellular carcinoma.

Authors:  J Belghiti; D Fuks
Journal:  Liver Cancer       Date:  2012-09       Impact factor: 11.740

4.  Toward current standards of donor right hepatectomy for adult-to-adult live donor liver transplantation through the experience of 200 cases.

Authors:  See Ching Chan; Sheung Tat Fan; Chung Mau Lo; Chi Leung Liu; John Wong
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

5.  Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS).

Authors:  Nuh N Rahbari; O James Garden; Robert Padbury; Mark Brooke-Smith; Michael Crawford; Rene Adam; Moritz Koch; Masatoshi Makuuchi; Ronald P Dematteo; Christopher Christophi; Simon Banting; Val Usatoff; Masato Nagino; Guy Maddern; Thomas J Hugh; Jean-Nicolas Vauthey; Paul Greig; Myrddin Rees; Yukihiro Yokoyama; Sheung Tat Fan; Yuji Nimura; Joan Figueras; Lorenzo Capussotti; Markus W Büchler; Jürgen Weitz
Journal:  Surgery       Date:  2011-01-14       Impact factor: 3.982

6.  Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.

Authors:  James Fung; Cindy Cheung; See-Ching Chan; Man-Fung Yuen; Kenneth S H Chok; William Sharr; Wing-Chiu Dai; Albert C Y Chan; Tan-To Cheung; Simon Tsang; Banny Lam; Ching-Lung Lai; Chung-Mau Lo
Journal:  Gastroenterology       Date:  2011-07-14       Impact factor: 22.682

7.  Living donor liver transplantation in high-risk vs. low-risk patients: optimization using statistical models.

Authors:  François Durand; Jacques Belghiti; Roberto Troisi; Olivier Boillot; Adrian Gadano; Claire Francoz; Bernard de Hemptinne; Alain Mallet; Dominique Valla; Jean Louis Golmard
Journal:  Liver Transpl       Date:  2006-02       Impact factor: 5.799

8.  Adult right-lobe living liver donors: quality of life, attitudes and predictors of donor outcomes.

Authors:  D A DuBay; S Holtzman; L Adcock; S Abbey; S Greenwood; C Macleod; A Kashfi; M Jacob; E L Renner; D R Grant; G A Levy; G Therapondos
Journal:  Am J Transplant       Date:  2009-05       Impact factor: 8.086

9.  Working up donors for high-urgency and elective adult-to-adult live donor liver transplantation.

Authors:  See Ching Chan; Sheung Tat Fan; Chi Leung Liu; Chung Mau Lo; Banny K Lam; Evelyn W Lee
Journal:  Liver Transpl       Date:  2007-04       Impact factor: 5.799

10.  Right lobe living donor liver transplantation with or without venovenous bypass.

Authors:  S T Fan; B H Yong; C M Lo; C L Liu; J Wong
Journal:  Br J Surg       Date:  2003-01       Impact factor: 6.939

View more
  5 in total

Review 1.  Post-hepatectomy liver failure.

Authors:  Rondi Kauffmann; Yuman Fong
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

Review 2.  Defining Post Hepatectomy Liver Insufficiency: Where do We stand?

Authors:  Kelly Lafaro; Stefan Buettner; Hadia Maqsood; Doris Wagner; Fabio Bagante; Gaya Spolverato; Li Xu; Ihab Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2015-06-11       Impact factor: 3.452

3.  Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis.

Authors:  Satoshi Kitai; Masatoshi Kudo; Naoshi Nishida; Namiki Izumi; Michiie Sakamoto; Yutaka Matsuyama; Takafumi Ichida; Osamu Nakashima; Osamu Matsui; Yonson Ku; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Liver Cancer       Date:  2016-05-03       Impact factor: 11.740

Review 4.  Perioperative Evaluation and Management of Patients With Cirrhosis: Risk Assessment, Surgical Outcomes, and Future Directions.

Authors:  Kira L Newman; Kay M Johnson; Paul B Cornia; Peter Wu; Kamal Itani; George N Ioannou
Journal:  Clin Gastroenterol Hepatol       Date:  2019-07-31       Impact factor: 11.382

5.  Phase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-Fluorouracil.

Authors:  Kazuomi Ueshima; Masatoshi Kudo; Masatoshi Tanaka; Takashi Kumada; Hobyung Chung; Satoru Hagiwara; Tatsuo Inoue; Norihisa Yada; Satoshi Kitai
Journal:  Liver Cancer       Date:  2015-10-21       Impact factor: 11.740

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.